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16CASE REPORT Open AccessActinobaculum schaalii an emerging pediatric
pathogen?
Petra Zimmermann1, Livia Berlinger2,3, Benjamin Liniger4, Sebastian Grunt5, Philipp Agyeman1
and Nicole Ritz1,6,7*Abstract
Background: Actinobaculum schaalii was first described as a causative agent for human infection in 1997. Since
then it has mainly been reported causing urinary tract infections (UTI) in elderly individuals with underlying
urological diseases. Isolation and identification is challenging and often needs molecular techniques. A. schaalii is
increasingly reported as a cause of infection in humans, however data in children is very limited.
Case presentation: We present the case of an 8-month-old Caucasian boy suffering from myelomeningocele and
neurogenic bladder who presented with a UTI. An ultrasound of the urinary tract was unremarkable. Urinalysis and
microscopy showed an elevated leukocyte esterase test, pyuria and a high number of bacteria. Empiric treatment
with oral co-trimoxazole was started.
Growth of small colonies of Gram-positive rods was observed after 48 h. Sequencing of the 16S rRNA gene
confirmed an A. schaalii infection 9 days later. Treatment was changed to oral amoxicillin for 14 days. On follow-up
urinalysis was normal and urine cultures were negative.
Conclusions: A.schaalii is an emerging pathogen in adults and children. Colonization and subsequent infection
seem to be influenced by the age of the patient. In young children with high suspicion of UTI who use diapers or
in children who have known abnormalities of their urogenital tract, infection with A. schaalii should be considered
and empiric antimicrobial therapy chosen accordingly.
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susceptibilityBackground
The genus Actinobaculum was first described as a cause
of human infection in 1997 [1]. Since the initial descrip-
tion of the genus A. schaalii has been the most fre-
quently reported human pathogen. It has mainly been
reported causing urinary tract infection (UTI) in elderly
people with underlying urological diseases. Like other
Actinomyces-like organisms it is suspected to be part of
the commensal flora of the human urogenital tract [1].
Since the introduction of molecular techniques into rou-
tine microbiological diagnosis, A. schaalii has increas-
ingly been reported as a cause of infection in humans* Correspondence: nicole.ritz@ukbb.ch
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distribution, and reproduction in any medium[2,3]. However data in children with A. schaalii infection
is very limited [4].
Case presentation
An 8-month-old boy with a lumbosacral myelomeningo-
cele surgically repaired shortly after birth and a hydro-
cephalus due to an Arnold-Chiari malformation was seen
at our clinic for a routine appointment. He had not previ-
ously suffered from a UTI and did not need regular
catheterization. On presentation he was afebrile and his
physical examination was normal. A cystomanometry per-
formed on the same day revealed an elevated bladder
pressure and a residual urine volume of 25 ml, confirming
the expected neurogenic bladder dysfunction. An ultra-
sound of the urinary tract was unremarkable. Urinalysis
from a catheter specimen showed an elevated leukocyte
esterase activity Microscopy of the urine showed more
than 20 leukocytes, 5 to 10 erythrocytes, plus a highentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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postulated and the patient was empirically treated
with oral co-trimoxazole (trimethoprim/sulfamethoxazole
5/25 mg/kg twice daily) for 7 days. According to standard
procedure urine cultures were set up on a CHROMagar
Orientation plate (Becton Dickinson AG, Basel, Switzer-
land) and a Columbia-Colistin-Nalidixic acid agar (CNA)
plate (Becton Dickinson, Basel, Switzerland) with 5%
sheep blood. Growth of small colonies was observed on
the CNA plate after 48 h of incubation at 35°C with 5%
CO2, corresponding to 10
4 colony forming units (CFU)/
ml. The growing Gram-positive rods were catalase-
negative and could not be identified by the API Coryne
System (bioMérieux, Geneva, Switzerland). For further
identification sequencing of the 16S rRNA gene by
MicroSeq500 16S rDNA bacterial identification kit (Ap-
plied Biosystems, Darmstadt, Germany) was performed.
Nine days later Basic Local Alignment Search Tool
(BLAST) analysis of the resulting 477 base pair sequence
was available and showed 100% identity with A. schaalii
strain BD04-00146 (GenBank accession number
AY957507.2).
Two weeks after the initial appointment the patient
was reviewed. Microscopy of the urine continued to
show 10 to 20 leukocytes and 10 to 20 erythrocytes per
high-power field with presence of bacteria. Blood ana-
lysis showed a C-reactive protein of 9 mg/l and a
leukocyte count of 7 × 109/l. The combination of a re-
peatedly abnormal urinalysis and growth of A. schaalii
in monoculture was considered diagnostic for a UTI.
According to current recommendations for the treat-
ment for A. schaalii infection oral amoxicillin (15 mg/kg
three times daily) was started [3,5]. The urine culture
from the same day showed growth of coagulase-negative
staphylococci. Eight days after starting amoxicillin,
results of the urinalysis were normal and urine cultures
were negative. The treatment with amoxicillin was con-
tinued for a total duration of 14 days.
Discussion
In children UTI is usually caused by gram-negative
organisms, including Escherichia coli, Klebsiella spp.,
Pseudomonas spp. and Proteus spp.[6]. A. schaalii, a re-
cently described pathogen, has to date mainly been asso-
ciated with UTI in elderly individuals.
A total of 47 cases of A. schaalii infection have been
published to date [1,3,4,7-20]. Of these, 41 cases (87%)
were reported in adults and only six cases in children
under the age of 15 years (Table 1). All of those six chil-
dren were symptomatic and treated with antibiotics.
Two of the three children with cystitis and the child
with pyelonephritis were febrile. In the case of the 15-
year old boy who presented with cystitis and the girl
with an intradural abscess the temperature was notspecified in the case report. Our case is, to our know-
ledge, the youngest child currently described with an
A. schaalii UTI. It is also the first case where A. schaalii
was treated in an asymptomatic child. In previous case
reports from both children and adults a high proportion
of individuals with an A. schaalii UTIs had an under-
lying urogenital pathology (83% and 85%, respectively).
All of the reported children were either using diapers or
had enuresis. In two children a second pathogen was
isolated: Klebsiella pneumoniae in a 3-year-old girl with
recurrent UTI [21] and non-hemolytic streptococci in a
9-month-old girl with intradural abscess [10]. Further
clinical details of all pediatric cases are summarized in
the Table 1.
Our case highlights the clinical features and challenges
in diagnosis and management of A. schaalii UTI. Isola-
tion and identification of A. schaalii using standard la-
boratory techniques is difficult. Notably, A. schaalii
requires CO2 enriched culture conditions and subse-
quent identification requires 16S rRNA sequencing.
Therefore the presence of Gram-positive rods in micros-
copy with a negative culture result should prompt the
search for unusual pathogens including A. schaalii.
This may lead to a significant delay in identification
resulting in prolonged or repeated antimicrobial therapy.
Its resemblance to normal skin flora further impedes
correct identification of the pathogen. In addition slow
growing bacteria such as A. schaalii can get overgrown
by faster-growing bacteria and therefore remain un-
detected. For this reason we opted to continue treatment
in our patient until urinalysis had normalized. Imple-
mentation of the newer Matrix-assisted laser desorption/
ionization-Time Of Flight (MALDI-TOF) technology in
routine diagnostic procedures may allow more rapid
identification of A. schaalii in future, which might
change the frequency of its detection.
A. schaalii has traditionally been thought to be part of
the commensal flora of the human urogenital tract [1].
However, there is evidence that colonization with
A. schaalii is dependent on risk factors including age,
the presence of diapers and enuresis. For example, in
asymptomatic patients above 60 years of age with nega-
tive results in a urine dipstick test, a real-time quantita-
tive PCR assay detected A. schaalii in 22% of urine
samples [2]. Similarly, in children suspected for UTI and
negative results in urine dipstick test from midstream
urine samples, PCR for A. schaalii from urine was posi-
tive in 36% (5 of 14) of children below three years of age
but negative in all 15 children tested between 3 and
15 years of age [21].
Colonization seems to be a risk factor for infection
with A. schaalii in children and adults as most case
reports have been described in the same age group
where colonization most frequently occurs.
Table 1 Clinical details of reviewed pediatric cases with Actinobaculum schaalii infection
Age
(years)
Sex Clinical
presentation
Specimen with A. schaalii Concomitant flora Underlying
urogenital tract
pathologies
Other underlying
risk factors
Antibiotic treatment Duration of
treatment
(days)
Outcome Reference
0.66 m cystitis urine none neurogenic bladder myelomeningocele
diaper
co-trimoxazole
followed by amoxicillin
7
14
recovery our case
0.75 f cauda equina
syndrome
pus from
intradural
abscess
non-hemolytic
streptococci
none syringomyelia
diaper
penicillin, metronidazol not specified recovery 10
3 f cystitis urine Klebsiella
pneumoniae
none recurrent UTI
diaper
trimethoprim
followed by amoxicillin
7
10
recovery 21
5 m pyelonephritis urine none pyeloureteral junction
obstruction
inborn right
hemispheric tissue
lesions with left-sided
hemiplegia epilepsy
amoxicillin/clavulanic acid
followed by vancomycin
2
14
recovery 4
13 m cystitis urine none neurogenic bladder enuresis pivampicillin
followed by mecillinam
followed by pivampicillin
20
10
14
re-infection
after 1 year
recovery
21
15 m cystitis urine none neurogenic bladder
vesicoureteral reflux
bladder diverticulum
myelomeningocele
paraplegia
amoxicillin/clavulanic acid 7 recovery *
*Personal communication, Reto Lienhard, Department of Microbiology, La Chaux-de-Fonds.
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A. schaalii and in contrast to previous reports in chil-
dren with A. schaalii UTI there were no clinical symp-
toms [4,10,21]. Similar colony counts have been found
in children considered to be colonized with A. schaalii,
however, none of these children had concomitant posi-
tive leukocyte esterase tests or pyuria [21]. In our patient
the combination of a repeatedly pathologic urinalysis in-
cluding a positive leukocyte esterase test and pyuria to-
gether with growth of 104 CFU/ml of a recognized
uropathogen in monoculture was considered sufficient
evidence for the diagnosis of a cystitis. The vast majority
of A. schaalii isolates are resistant to co-trimoxazole and
ciprofloxacin, which are frequently used as empiric treat-
ment in UTI in children and adults respectively. Current
recommendations for the choice of antibiotic treatment
for A. schaalii infection are amoxicillin or cephalospor-
ins [5]. There is limited data from in vitro susceptibility
testing suggesting that gentamicin, vancomycin, linezo-
lid, nitrofurantoin and mecillinam are potential alterna-
tive treatment options [5,22]. The optimal duration of
antibiotic treatment for A. schaalii infection is currently
unknown. Most case reports suggest treatment duration
of 7 to 14 days. Therefore we repeated the urine culture
after eight days of antibiotic treatment, and stopped
treatment after 14 days when negative culture results
were available.
Conclusions
A. schaalii is an emerging pathogen in both children and
adults. Colonization and subsequent infection seem to
be influenced by a number of factors in particular age of
the patient. In young children with high suspicion of
UTI who use diapers or children who have known ab-
normalities of their urogenital tract, infection with
A. schaalii should be considered and empiric antimicro-
bial therapy chosen accordingly. Further studies are
needed to evaluate additional risk factors and to define
optimal choice and duration of antibiotic treatment.
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